GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Purchased by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. raised its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,803 shares of the company’s stock after purchasing an additional 248 shares during the period. Ameritas Investment Partners Inc.’s holdings in GE HealthCare Technologies were worth $1,618,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in GE HealthCare Technologies in the fourth quarter valued at about $29,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at approximately $30,000. BNP Paribas bought a new position in GE HealthCare Technologies during the first quarter worth $30,000. Sachetta LLC bought a new position in GE HealthCare Technologies during the fourth quarter worth $31,000. Finally, Rise Advisors LLC boosted its holdings in GE HealthCare Technologies by 241.4% in the first quarter. Rise Advisors LLC now owns 338 shares of the company’s stock worth $31,000 after purchasing an additional 239 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on GEHC shares. Mizuho reduced their price target on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Argus raised their target price on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Bank of America reduced their price target on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. The Goldman Sachs Group initiated coverage on shares of GE HealthCare Technologies in a research note on Thursday, May 30th. They set a “neutral” rating and a $87.00 price objective on the stock. Finally, Citigroup boosted their target price on GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.09.

Insider Transactions at GE HealthCare Technologies

In related news, CEO Jan Makela sold 20,227 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $81.57, for a total value of $1,649,916.39. Following the completion of the transaction, the chief executive officer now owns 63,348 shares of the company’s stock, valued at approximately $5,167,296.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Jan Makela sold 20,227 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $81.57, for a total value of $1,649,916.39. Following the completion of the sale, the chief executive officer now owns 63,348 shares in the company, valued at $5,167,296.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frank R. Jimenez bought 1,315 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was acquired at an average cost of $76.52 per share, with a total value of $100,623.80. Following the transaction, the insider now owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The disclosure for this purchase can be found here. Insiders have sold a total of 90,482 shares of company stock valued at $7,369,137 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC traded up $0.07 during trading on Wednesday, hitting $80.89. The company had a trading volume of 934,332 shares, compared to its average volume of 3,086,314. GE HealthCare Technologies Inc. has a 52 week low of $62.35 and a 52 week high of $94.50. The business’s 50-day moving average is $78.75 and its 200 day moving average is $82.15. The company has a market cap of $36.92 billion, a P/E ratio of 23.63, a PEG ratio of 2.92 and a beta of 1.20. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Tuesday, April 30th. The company reported $0.90 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.90. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The company had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.80 billion. During the same period in the previous year, the firm earned $0.85 earnings per share. GE HealthCare Technologies’s revenue for the quarter was down 1.2% compared to the same quarter last year. Equities research analysts predict that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Shareholders of record on Friday, July 19th will be issued a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.15%. The ex-dividend date is Friday, July 19th. GE HealthCare Technologies’s payout ratio is 3.51%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.